Emily Jairam
Physician Assistant · Long Beach, CANPI 1154806487
Payments from drug & device makers
Across 1,264 payments — averaging $18.79 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$3K
- UCB, Inc.$2K
- Teva Pharmaceuticals USA, Inc.$1K
- Biogen$1K
- Amgen$1K
- Lundbeck LLC$1K
- plus $13K from 54 others
What the payments were for
- Food & beverage$23,26298%
- Education$4892%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- NURTEC ODT$506
- Ponvory$160
- UPLIZNA$150
- Vumerity$135
- UBRELVY$125
- NUPLAZID$125
- QULIPTA$123
- ZEPOSIA$118
- EMBOLD Fibered$104
- AUSTEDO$104
How this compares
$23,751 in reported general payments places this provider in the 95th percentile of 10,423 physician assistant providers in California.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| PrivigenImmun Glob G(Igg)/Pro/Iga 0-50 | 14 | $314,167 |
| OctagamImmun Globg(Igg)/Malt/Iga Ov50 | 11 | $261,548 |
| AustedoDeutetrabenazine | 12 | $122,897 |
| Emgality PenGalcanezumab-Gnlm | 137 | $112,028 |
| Kesimpta PenOfatumumab | 12 | $97,625 |
| QuliptaAtogepant | 64 | $95,560 |
| Aimovig AutoinjectorErenumab-Aooe | 64 | $58,590 |
| Oxtellar XrOxcarbazepine | 26 | $50,659 |
| UbrelvyUbrogepant | 26 | $40,940 |
| Nurtec OdtRimegepant Sulfate | 28 | $40,055 |
| Topiramate ErTopiramate | 11 | $9,804 |
| ZtlidoLidocaine | 11 | $8,517 |
| Lacosamide | 55 | $7,321 |
| DayvigoLemborexant | 19 | $6,039 |
| Memantine Hcl ErMemantine Hcl | 21 | $4,688 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| CSL BehringPrivigen | $278 | $314,16714 claims |
| PfizerOctagam, Nurtec Odt | $504 | $301,60439 claims |
| AbbVieQulipta, Ubrelvy | $3,266 | $136,50090 claims |
| Teva Pharmaceuticals USA, Inc.Austedo | $1,425 | $122,89712 claims |
| Supernus Pharmaceuticals, Inc.Oxtellar Xr | $200 | $50,65926 claims |
| Scilex Pharmaceuticals Inc.Ztlido | $79 | $8,51711 claims |
| Eisai Inc.Dayvigo | $379 | $6,03919 claims |
| Upsher-smith Laboratories LLCTopiramate | $196 | $86191 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 10,423 physician assistant providers in California.
Other physician assistant in Long Beach
- Amanda NelsonLong Beach$45K
- John QuigleyDowney$2.9M
- Andrea NguyenIrvine$1M
- Mikhail AlperMadera$889K
- Erin JensenUpland$716K
- Franklin ClineSacramento$458K
- Carla CrespoMarina del Rey$297K
- Katherine OsakiEl Centro$274K
- Shawna JonesFountain Valley$266K
- Heather AustinSalinas$219K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.